Tumours require blood to emerge and spread. That is why scientists at The University of Texas MD Anderson Cancer Center believe that targeting blood vessel cells known as pericytes may offer a potential new therapeutic approach when combined with vascular growth factors responsible for cell death.
A study from MD Anderson, Beth Israel Medical Center, Harvard Medical School, and the École Polytechnique Fédérale de Lausanne looked at how cellular signaling by vascular growth factors called angiopoietin-2 (ANG2), when combined with depletion of pericytes, may decrease breast cancer tumour growth that spreads to the lungs. Targeting pericytes and ANG2 signaling may also offer new potential therapy options for treatment of some breast cancers. The opensource study is published in the journal Cell Reports.
The current study showed that angipoietin signaling is a key metastasis promoting pathway associated with abnormal tumour blood vessels with poor pericytes coverage. When combined with pericyte loss during the late phases of tumour progression, it is possible to reduce both primary tumour growth and metastatic disease.
Previous strategies to target how tumours develop blood supplies have looked at pericyte depletion. Pericytes, cells that wrap around capillary cells throughout the body, have the ability to contract, thus regulating blood flow. Since angiopoietins are blood vessel growth factors that provide the green light for new arteries or veins to grow, the combination of the two is of interest to cancer researchers.
The team state that targeting of ANG2 signaling in tumours with abnormal blood vessels with low pericyte coverage appeared to restore vascular stability and decreased tumour growth and metastasis in lung cancer mouse models. The team also found that ANG2 was tied to poor outcome in patients with breast cancer. These results emphasize the potential for therapies targeting in advanced tumours with poor quality blood vessels.
Source: MD Anderson
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.